kelch like family member 2Genealiases: ABP-KELCH · MAV · MAYVEN
Q-omics provides the consensus-scored KLHL2 profile across patient tissues and cancer cell-line models. KLHL2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, KLHL2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, KLHL2 RNA expression shows 20,037 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, KIRC, and UVM as cancer lineages where KLHL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL2 survival associations across molecular data types. KLHL2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL2 RNA expression–survival associations across cancer types. High KLHL2 expression shows unfavorable associations in SCLC, MESO, HNSC, LUSC and LUAD, but favorable associations in SKCM. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify SCLC as the clearest survival context for KLHL2 RNA expression.
This table summarizes KLHL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KLHL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL2 shows lower tumor expression in KIRC, KICH, LUSC, BRCA and KIRP and higher tumor expression in THCA. The KIRC box plot shows higher KLHL2 RNA expression in normal versus tumor tissue (log2 FC = −0.817, t-test p < 0.001).
This table shows molecular features associated with KLHL2 in patient tissues and cancer cell lines. In patient samples, KLHL2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
